Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/lenacapavir versus Biktarvy in virologically suppressed adults with HIV-1
2023-510022-33-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of bictegravir and lenacapavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of participants with HIV-1 RNA at least 50 copies/mL at Week 48. Planned start Oct 2024; status: authorised.
02
Drugs
bictegravirlenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2023-510022-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510022-33-00.